2 - Neoplasia Flashcards
What prevents a benign tumor from becoming malignant?
They don’t develop subsequent mutations, or don’t develop the right ones to metastasize.
They retain well-controlled growth, benign histologic features.
What allows malignant tumors to metastasize?
They develop subsequent multiple mutations, overexpressions, acquired enzyme pathways (eg telomerases), loss of cell adhesion markers
They develop capacity for invasion & metastasis
They acquire gross & microscopic features of malignancy
Steps in normal physiologic cell proliferation
GF binds TM GF-Receptor Signal Transduction 2nd messengers & kinase pathway DNA transcription Cell Cycling (G1-S-G2-M)
Inactive RAS
Bound to GDP
Activated RAS
Switched out by GTP
Active RAS inactivates itself by
Hydrolyzing GTP to GDP.
Mutation preventing this inactivation leads to cancer.
The most commonly mutated proto-oncogene in human tumors
RAS
Steps downstream of RAS
PI3K
AKT
mTOR
or
RAF
MAPK
KRAS
Human homologue of the Kirsten Rat Sarcoma Oncogene
NRAS
Human homologue of the Neuroblastoma RAS Oncogene
Melanoma steps
Benign Nevus Dysplastic Nevus Radial Growth Phase Vertical Growth Phase Metastatic Melanoma
Melanoma - Benign Nevus
BRAF mutation
Benign, limited growth
Melanoma - Dysplastic Nevus
Previous: BRAF
CDKN2A loss
PTEN loss
Premalignant, lesions may regress.
Random atypia
Melanoma - Radial Growth Phase
Previous:
BRAF mutation
CDKN2A loss
PTEN loss
Increased CD1
Decreased differentiation
Unlimited hyperplasia
Cannot grow in soft agar
Clonal proliferation
Melanoma - Vertical Growth Phase
Previous: BRAF mutation CDKN2A loss PTEN loss Increased CD1
E-Cadherin Loss N-Cadherin Expression αVβ3 Integrin Expression MMP-2 Expression Survivin Reduced TRPM1
Crosses basement membrane
Grows in soft agar
Forms tumor
Melanoma - Metastatic
Previous: BRAF mutation CDKN2A loss PTEN loss Increased CD1 E-Cadherin Loss N-Cadherin Expression αVβ3 Integrin Expression MMP-2 Expression Survivin
Absent TRPM1
Dissociates from primary tumor
Grows at distant sites
ERBB1 (EGF receptor)
Overexpressed in 80% of squamous cell lung cancer
HER2/NEU (ERBB2)
Amplified in 25 - 30% of breast cancers
Bad prognosis
Treat with HER2/NEU antibodies to block the signals of cell division
Benign Tumor - Gross Path
Usually Small (grows to a limited size, then stops) Well-Circumscribed Closely resembles tissue of origin Does not invade or metastasize. May be encapsulated in fibrous tissue
Malignant Tumor - Gross Path
May be small or may reach large size Poorly circumscribed Differentiation may range from well to poorly differentiated. Cytologic features of malignancy Capable of invasion and metastasis.
Malignant Tumor - Histo
Increased Nucleus:Cytoplasm ratio Nuclear hyperchromatism Prominent Nucleoli Nuclear Pleomorphism Increased mitotic rate
Squamous Cell Carcinoma - Where could it come from?
Skin Esophagus Lung Cervix Anus
Identify squamous cell carcinoma of the skin
Look for keratin pearls
Squamous Cell Carcinoma - Identifier
Tonofilaments (Intercellular bridges)
Perpendicular between tumor cells
Adenocarcinoma
Malignant gland formation
Back-to-back gland growth
Nuclear features of malignancy
Often necrotic (due to outgrowth of blood supply)
Sarcoma
Malignant tumor of the mesenchymal tissue (adipose, fibroblasts, muscle)
Ex: Leiomyosarcoma of the uterus
Gross: Hemorrhage, necrosis
Microscopic: Pleomorphic nuclei, mitotic figures
Lymphoma
“Fish-Flesh appearance”
Malignant lymphoma in LNs
Sarcomas
Malignant Lymphoma
Tumors derived from T cells and B cells